Importance (limit:150): 1 2 Colorectal cancer (CRC) is a major public health concern; there were approximately 135,430 3 new cases in 2017, and CRC is the second leading cause of cancer-related deaths for both men 4 and women in the US (1). Many factors have been linked to CRC development, the most recent 5 of which is the gut microbiome. Pre-clinical models support that enterotoxigenic Bacteroides 6 fragilis (ETBF), among other bacteria, induce colon carcinogenesis. However, it remains unclear 7 if the virulence determinants of any pro-carcinogenic colon bacterium induce DNA mutations or 8 changes that initiate clonal CEC expansion. Using a reductionist model, we demonstrate that 9
2 Abstract (limit:250): 1 2 Enterotoxigenic Bacteroides fragilis (ETBF) is a gram negative, obligate anaerobe member of the 3 gut microbial community in up to 40% of healthy individuals. This bacterium is found more 4 frequently in people with colorectal cancer (CRC) and causes tumor formation in the distal 5 colon of mice heterozygous for the adenomatous polyposis coli gene (Apc +/-); tumor formation 6 is dependent on ETBF-secreted Bacteroides fragilis toxin (BFT). Though some of the immediate 7 downstream effects of BFT on colon epithelial cells (CECs) are known, we still do not 8 understand how this potent exotoxin causes changes in CECs that lead to tumor formation and 9 growth. Because of the extensive data connecting alterations in the epigenome with tumor 10 formation, initial experiments attempting to connect BFT-induced tumor formation with 11 methylation in CECs have been performed, but the effect of BFT on other epigenetic processes, 12 such as chromatin structure, remains unexplored. Here, the changes in chromatin accessibility 13 (ATAC-seq) and gene expression (RNA-seq) induced by treatment of HT29/C1 cells with BFT for 14 24 and 48 hours is examined. Our data show that several genes are differentially expressed 15 after BFT treatment and these changes correlate with changes in chromatin accessibility. Also, 16 sites of increased chromatin accessibility are associated with a lower frequency of common 17 single nucleotide variants (SNVs) in CRC and with a higher frequency of common differentially 18 methylated regions (DMRs) in CRC. These data provide insight into the mechanisms by which 19 BFT induces tumor formation. Further understanding of how BFT impacts nuclear structure and 20 function in vivo is needed. 21 22 BFT2 treatment). This initial analysis revealed that only a fraction (40% at 24 hours and 35% at 1 48 hours) of the peaks identified by ATAC-seq are affected by BFT2 treatment, and that BFT2 2 treatment appears more likely to open chromatin than to close it (~11:3 ratio at 24 hours; ~5:3 3 ratio at 48 hours) ( fig 1B) . We next analyzed the overlap of our BFT2-opened peaks and BFT2-4 closed peaks between 24 and 48 hours in order to determine if BFT2-induced changes in 5 chromatin accessibility are stable. We found that only 13.4% (4989 peaks) of 24 hours and 48 6 hours BFT2-opened peaks overlap, and 4.55% (743 peaks) of 24 hours and 48 hours BFT2-closed 7 peaks overlap ( fig 1B) . These results emphasize the dynamic nature of BFT2-induced changes of 8 chromatin accessibility. 9 10 To explore how BFT2 affects peak distribution throughout the genome, we performed a 11 detailed analysis on the BFT2-opened and BFT2-closed chromatin regions (i.e. the regions of the 12 genome affected by BFT2 treatment). When we analyze the distribution of these peaks, we see 13 that more of BFT2-opened and BFT2-closed peaks are located within intergenic regions and 14 coding regions than promoter regions (Table 1 ). To determine if this distribution was a 15 byproduct of the ATAC-seq assay or a specific effect of BFT2, we compared those peak 16 distributions to the distribution present in our baseline and BFT2-treated samples. This analysis 17 reinforced that more of the BFT2-opened and BFT2-closed peaks are located within intergenic 18 and coding regions, while less are located within promoter regions (Table 1 ). Although we 19 expect that the effect in all three regions is important, these results suggest that chromatin 20 accessibility is affected differentially across the genome by BFT2. 21 22 BFT2 treatment induces changes in gene expression that are more pronounced at 24 hours 1 than 48 hours 2 3 To examine the relationship between gene expression and chromatin state, we performed 4 RNA-seq on the same samples used for ATAC-seq analysis. While the effect of BFT2 treatment 5 on select genes at relatively early time points has been studied (16, 17) , how this toxin affects 6 genome wide expression and whether these effects persist is still unknown. After treatment 7 with BFT2 for 24 hours, 70 genes were differentially expressed (P-value < 0.01). Of these genes, 8 41 showed a decrease in gene expression, while 29 showed an increase in gene expression ( fig  9   2A , supplementary table 1). After BFT2 treatment for 48 hours, we found only 16 differentially 10 expressed genes (P-value < 0.01); 3 showed a decrease in gene expression and 13 showed an 11 increase in gene expression ( fig 2B, supplementary table 2 ). This result follows a trend seen 12 throughout our analyses and the literature (7, 16, 18) in which BFT2 has a more potent effect 13 on CECs at 24 hours after toxin treatment that seems to diminish by 48 hours. A lineplot of the 14 top 16 differentially expressed genes at 24 and 48 hours shows that gene expression at the two 15 time points tends to differ; genes differentially expressed at 24 hours tend to move closer to 16 baseline levels by 48 hours, while genes differentially expressed at 48 hours tend to have 17 expression levels closer to baseline at 24 hours (supplementary fig 1) . Notably, none of the 18 genes differentially expressed at 24 hours show statistically significant differential expression at 19 48 hours as well. These data reinforce the observation that BFT2-induced gene expression 20 changes are highly dynamic, and time specific, similar to BFT2-induced changes in chromatin 21 accessibility. 22 1 To perform a Gene Set Enrichment (GSE) analysis on the list of genes that were differentially 2 expressed at 24 hours and 48 hours after BFT2 treatment, the cutoff for significance was 3 relaxed to a P-value of less than 0.05. The GSE analysis revealed several processes that were 4 overrepresented in our list of upregulated and downregulated genes (fig 2c) . Specifically, at 24 5 hours after BFT2 treatment, expression of transcription factors involved in nucleic acid binding 6 were downregulated. At 48 hours after BFT2 treatment, genes related to the cell cycle, 7 chromosome organization and response to DNA damage, among others, were upregulated (fig 8 2C). 9 10
Chromatin accessibility correlates with gene expression at baseline and at 24 hours after BFT2 11
treatment 12
13
We next tested the hypothesis that BFT2-induced changes in chromatin accessibility correlate 14 with BFT2-induced changes in gene expression. First, we classified genes by promoter 15 chromatin accessibility status in our 24hr untreated (baseline) sample. Only promoter peaks 16 were used because of the intuitive connection between open promoter chromatin and changes 17 in gene expression. Those genes that contained an ATAC-seq peak overlapping their promoter 18 region were categorized as "open" and those without a peak were categorized as "closed". We 19 then extracted normalized gene expression values (transcripts per million-TPM) for each of 20 these genes to determine if the average gene expression values were different for the two 21 groups. We found that on average, gene expression was statistically higher among genes that 22 were "open" in our 24hr baseline sample compared to those that were "closed" (P-value < 2e -1 16 ) ( fig 3A) . 2 3 Next, we examined the correlation between changes in chromatin accessibility and changes in 4 gene expression at the same time points. To do this, we again focused on BFT-opened and BFT-5 closed peaks which overlapped with gene promoter regions. We then calculated the 6 logarithmic fold-change (Log2FC) expression values for each of these genes at 24 or 48 hours 7 after BFT2 treatment. We found that genes with a BFT2-opened peak overlapping their 8 promoter had a three-fold higher Log2FC in gene expression after 24 hours of BFT2 treatment 9 than genes with a BFT2-closed peak at the same time point. At 48 hours after BFT2 treatment, 10 we found no difference in Log2FC gene expression (fig 3 B -C). A similar analysis can be 11 performed for the 86 genes that show statistically significant differences in gene expression 12 after BFT2 treatment (fig 2 A-B, Supplementary tables 1, 2). Among those, 7 contained BFT2-13 opened peaks overlapping their promoter (6 at 24 hours and 1 at 48 hours). Of these genes, 5 14 showed an increase in gene expression, while 2 showed a decrease. No BFT2-closed peaks 15 overlapped with the promoters of these 86 genes at either time point (supplementary tables 1, 16 2). Taken together, these results suggest that at 24 hours after BFT2 treatment, changes in 17 chromatin structure largely correlate with changes in gene expression, but this relationship 18 disappears by 48 hours. 19 20 Treatment with BFT2 causes increased chromatin accessibility at transcription factor binding 21 sites 22 1 Gene expression is regulated via multiple mechanisms, including the binding of transcription 2 factors to enhancers and gene promoters. Therefore, we also wanted to test the hypothesis 3 that BFT2-induced changes in chromatin accessibility impact transcription factor binding sites 4 and thus gene expression. This can be done by looking for specific transcription factor motifs at 5 sites of altered chromatin accessibility, or by calculating the overlap of sites of altered 6 chromatin accessibility with sites of transcription factor binding. This latter approach is only 7 available for a handful of transcription factors, such as CTCF, which have been extensively 8 profiled via Chip-seq experiments in various cell types (19). 9
10
We first used the haystack_bio bioconda package to query our ATAC-seq data for specific 11 transcription factor motifs. This analysis revealed several transcription factor motifs that are 12 enriched in our BFT2-treated or baseline samples (Tables 2,3 ; Supplementary tables 5,6). In 13 contrast to the BFT2-dependent dynamic chromatin changes identified in our earlier analyses 14 Table 1 ), many of the most enriched transcription factor motifs identified are present 15 after both 24 and 48 hours of BFT2 treatment. Notably, these include JUND, JDP2, FOSL1, JUNB, 16 FOS, FOS:JUN and ZBTB33, many of which are downstream of mitogen-activated protein kinase 17 (MAPK) pathways previously shown to be modulated by BFT2 (18, 20, 21) . In subsequent 18 analyses, we specifically examined FOSL1, as it was the only transcription factor whose 19 expression was upregulated 24 hours after BFT2 treatment. We noted that while several 20 FOSL1-regulated genes were also upregulated after BFT2 treatment, a near equal proportion 21 were also downregulated (supplementary tables 3,4). For FOSL1 to augment gene expression, it 22 needs to bind to an accessible DNA-binding site, so we next examined the FOSL1-regulated 1 genes and classified them according to accessibility 24 hours after BFT2 treatment, as 2 determined by ATAC-seq. We found that 6 of 7 genes with accessible DNA binding sites 3 showed an increase in expression after BFT2 treatment, and only 1 of 6 genes without an 4 accessible DNA binding site showed an increase in expression after BFT2 treatment 5 (supplementary tables 3,4). 6 7 While changes in promoter chromatin structure have been most extensively investigated, and 8 provide many avenues for exploration, our data indicate that BFT2-induced changes in 9 chromatin structure occur more frequently in intergenic regions. We hypothesized that these 10 intergenic chromatin accessibility changes may affect chromatin architecture more globally and 11 sites of CTCF binding specifically. CTCF is a DNA binding protein that regulates global chromatin 12 structure by mediating chromatin looping via binding to and bringing together distant regions 13 of the genome (19). The CTCF motif was enriched in our ATAC-seq data after 24 hours, but not 14 48 hours, of BFT2 treatment (Tables 2, 3 ). To further investigate this enrichment, we calculated 15 a jaccard index for the overlap of CTCF binding sites in CACO-2 cells and HT29/C1 cells (the 16 latter using our ATAC-seq data); both cell lines are human transformed colon epithelial cell 17 lines. We found that after 24 hours of BFT2 treatment, but not 48 hours, the HT29/C1/CACO-2 18 jaccard index was increased by 1.13 fold (data not shown). These results again suggest that 19 sites in the genome that show increases in chromatin accessibility after BFT2 treatment are 20 more likely to also be sites of CTCF binding. 21
22
Chromatin accessibility is associated with differential DNA methylation and DNA mutation 1 2
The previous analyses help us better understand how BFT2 alters chromatin accessibility in 3 CECs and to connect chromatin changes with anticipated gene expression changes. However, 4 they do not help us understand how changes in chromatin accessibility may contribute to 5 common DNA-modifications found in CRC. To explore this, we looked for a correlation between 6 BFT2-induced changes in chromatin accessibility and single nucleotide variants (SNVs) and 7 common sites of differential methylation (DMRs) in CRC. SNVs and DMRs were extracted from 8 the COSMIC database. We calculated the proportion of peaks in each sample that overlapped 9 with a common SNV or DMR. We then used a chi-square test to compare our treated and 10 untreated samples in order to determine if the proportion of peaks overlapping a SNV or DMR 11 differed after treatment of HT29/C1 cells with BFT2. 12 13 Correlating our chromatin accessibility changes with SNVs in CRC allows us to explore the 14 effects of BFT2-induced chromatin accessibility changes in coding regions of the genome, where 15 specific chromatin structure states have been linked to decreased mutation rates in cancer (13). 16
In contrast, examining DMRs allows us to explore whether BFT2-induced chromatin accessibility 17 is associated with hypermethylation of CpG islands in promoter regions, or hypomethylation of 18 short interspersed nucleotide elements (SINEs) (Table 4 ). Similar to our prior data, the effect of BFT2 was more pronounced 24 3 hours after cell treatment. Thus, contrary to our hypothesis, these data suggest that regions of 4 the genome with BFT2-induced increases in chromatin accessibility are less likely to contain 5 SNVs commonly found in CRC. 6 7 In contrast, our DMR analysis found that a larger proportion of BFT2-induced chromatin 8 accessibility peaks overlap with common DMRs in CRC 48 hours [OR(95%CI): 1.094(1.018-9 1.176)], but not 24 hours [OR(95% CI): 1.037(0.965-1.114)] after BFT2 treatment (Table 4 ). This 10 result supports a commonly held paradigm that chromatin changes come first, followed by 11 methylation changes (22). When we further parsed the data to analyze regions of 12 hypermethylation and hypomethylation individually, the results differed slightly, but 13 consistently showed a larger proportion of peaks overlapping with common DMRs in CRC after 14 BFT2 treatment (Table 4) . Thus, analysis of DMRS supported our hypothesis that BFT2-induced 15 regions of increased chromatin accessibility are more likely to contain sites of differential 16 methylation found in CRC. 17
18
Discussion 19 20 Our data support that acute BFT2 treatment of colon epithelial cells (CECs) leads to rapid onset 21 and dynamic, but limited changes in chromatin accessibility. These changes in chromatin 22 accessibility could be associated with BFT2-induced changes in gene expression. We observed 1 changes in both chromatin accessibility and gene expression over a 48-hour period, with the 2 strongest changes occurring at 24 hours, then relaxing to baseline by 48 hours. Our results 3 corroborate previous observations about the acute onset of BFT2 action on epithelial cells in 4 vitro and in vivo (7, 16, 18) . 5 6 Our RNA-seq data identifies several genes and pathways that are differentially regulated after 7 BFT2 treatment. The pathways identified, particularly at 48 hours, include those involved in the 8 DNA damage response and cell cycle regulation, both germane to previously reported induced CEC changes in vitro and in vivo. Namely, BFT2 has been shown to induce DNA double 10 strand breaks and modulate apoptosis in vitro (17, 20) and ETBF similarly induces DNA double 11 strand breaks (16) as well as colon carcinogenesis in vivo (23). In addition, our study also 12 identified several new genes that may explain how BFT2 contributes to tumorigenesis by 13 allowing other bacteria to invade the mucus layer and bind to CECs. Specifically, BFT2 causes 14 upregulation of CEACAM6 and MUC16, and downregulation of MUC2. CEACAM6 acts as a 15 receptor for adherent-invasive E.coli, a particular strain of E. coli that has recently been 16 implicated in the development/progression of CRC in individuals with FAP (24) and has 17 previously been associated with sporadic CRC (25). MUC2, the major MUC protein present in 18 human colonic mucus, is notably downregulated after BFT2 treatment, potentially contributing 19 to mucus invasion by tumorigenic E.coli. The upregulation of MUC16, a particular MUC variant 20 that is not normally expressed in the colon, may represent a compensatory mechanism (i.e., an 21 16 attempt to protect CECs after MUC2 downregulation). Collectively, these results may begin to 1 explain how ETBF works with other bacteria to promote tumor formation and growth. 2 3 Several previous studies have shown that chromatin structure in gene promoter regions 4 correlates with gene expression (26, 27) . Our study took this a step further by showing that 5 acute changes in chromatin accessibility correlate with acute changes in gene expression. 24 6 hours after BFT2 treatment, increases in chromatin accessibility generally correlated with 7 increases in gene expression while decreases in chromatin accessibility correlated with 8 decreases in gene expression. On the other hand, at 48 hours, no significant association is seen 9 between changes in chromatin accessibility and gene expression. This lack of association is 10 likely due to the limited gene expression changes that remain 48 hours after BFT2 treatment 11 and underscores a trend that is seen throughout most of our data whereby changes due to 12 BFT2 treatment are greater 24 hours after treatment and approach baseline levels by 48 hours. 13
This pattern is also corroborated by previous in vitro data that has shown that the effect of 14 BFT2 on gene expression in CECs is rapid and appears to decay quickly (7, 16, 18) , although 15 biologic effects such as CEC proliferation persist for at least 72 hours in vitro (7). pathway known to be activated by BFT2 (18, 20, 21) . After BFT2 treatment, we expected to see 21 increased expression of genes which are regulated by these particular transcription factors, but 22 chromatin opening alone appeared insufficient to drive changes in gene expression of these JNK 1 pathway genes. Hence, we looked for transcription factors that had both an enriched binding 2 motif and increased gene expression after BFT2 treatment. FOSL1 was the primary candidate 3 revealed by our analysis. We found that though presence of a FOSL1 binding site alone was 4 unable to predict differential gene expression after BFT2 treatment, when coupled to promoter 5 chromatin accessibility, an excellent concordance with increased gene expression was detected. 6
This finding exemplifies how integration of chromatin accessibility and gene expression data 7 can be applied to understand how BFT2 acts on CECs. We needed to use both types of data to 8 correctly surmise that transcription factor upregulation, enrichment of transcription factor 9 binding motifs, and the presence of open chromatin in the promoter region all contribute to 10 BFT2-induced gene regulation. 11 12 Because CRC usually results from a series of genetic mutations, and can be transformed by 13 changes in methylation patterns, any potential interaction between BFT2, chromatin 14 accessibility, and common SNVs/DMRs in CRC is important. Herein, we found a BFT2-induced 15 increase in chromatin accessibility at sites of common DMRs in CRC and a decrease at sites of 16 common SNVs in CRC. Increased methylation after inoculation of mice with ETBF has been 17 suggested previously. Specifically, studies by O'Hagan and colleagues have shown that binding 18 of DNMT1 (DNA methyltransferase 1) at promoters of low-expressing genes is upregulated 19 after ETBF murine colonization (11). While this study implicates ETBF, and thus BFT, in DNA 20 hypermethylation, no studies to date have explored the connection between BFT and 21 hypomethylation. Our data suggest that BFT2-induced changes in chromatin accessibility may 22 have dual effects on chromatin methylation patterns (fig 4) . We hypothesize that increased 1 chromatin accessibility is, at least, one step critical to chromatin methylation pattern changes in 2 response to BFT2. This is important because hypermethylation can lead to silencing of tumor 3 suppressor genes and hypomethylation can lead to upregulation of transposable elements that 4 may reintegrate into tumor suppressor or proto-oncogenes. In the future, bisulfite sequencing 5 experiments can be conducted to definitively correlate sites of methylation change after BFT2 6 treatment with sites of altered chromatin accessibility. 7
8 Several experiments, conducted across a variety of species, have also shown that chromatin 9 accessibility may be inversely correlated with rates of specific DNA mutations (28-30). One 10 study in particular showed that DNase accessible euchromatin was protected from UV-induced 11 DNA damage, while lamina-associated heterochromatin was more susceptible to damage (14) . 12
This study is of particular importance because it investigated carcinogenesis-related DNA 13 damage. Our data suggest that BFT2-induced decreases in chromatin accessibility are 14 correlated with frequently mutated areas, suggesting that BFT2-induced chromatin changes 15 may increase the chances of mutations. Such a hypothesis would require significant further 16 testing to determine its accuracy -this could be done by sequencing BFT2-treated and 17 untreated cells in order to determine if BFT2 treatment increases the mutation rate. If so, sites 18 of increased mutation frequency could be identified and correlated with sites of BFT2-induced 19 chromatin accessibility change. 20
19
Our study has several limitations that provide avenues for future experiments. Most notably, 1 our experiments were performed on HT29/C1 cells, a colon carcinoma cell line. These cells 2 contain several mutations that may lead them to respond differently to BFT2 than normal CECs. 3
As a result, these experiments should be confirmed in a primary cell culture system, or ideally, 4 in vivo in a mouse model or from human samples with and without ETBF colonization. Our 5 study, by design, was also performed over only an early time window. In vitro studies with BFT 6 best mimic the earliest in vivo events whereby ETBF induces CEC changes and colitis by ~24 7 hours after murine colonization (31). In contrast, the persistent CEC exposure to BFT afforded 8 by chronic ETBF colonization in vivo cannot be reliably modeled in vitro, in part, because of CEC 9 uptake and degradation of BFT (32). Thus, additional in vivo studies are warranted since ETBF 10 murine colonization is persistent and associated with ongoing IL-17-dominant inflammation and 11 CEC hyperplasia after one year in C57Bl/6 mice (31, 33). Ultimately, we want to know which 12 BFT-induced chromatin and gene expression changes persist and contribute to tumor 13 formation. Verifying these experiments in an in vivo system will help answer some of the 14 questions proffered by these data. 15
16
The experiments reported herein provide additional insight into the effect of BFT2, a bacterial 17 exotoxin linked to CRC pathogenesis, on CECs. We have identified new associations between 18 BFT2-induced chromatin accessibility and gene expression changes, and also correlated these 19 changes with previously published data on BFT2-induced signal transduction and DNA 20 modifications that may contribute to tumor formation or growth. We need to better 21 20 understand how BFT2 affects the genome and epigenome of CECs to determine if 1 asymptomatic carriers of ETBF are at increased risk for colon tumorigenesis. chromatin accessibility at baseline. Genes were first sorted by the presence of a peak in their 11 promoter in the 24hr baseline sample. Genes with a promoter peak were considered "open" 12 while those without a peak were considered "closed." Log transcripts per million (TPM) gene 13 expression values were then extracted and compared. The P-value was calculated by comparing 14 the gene expression of genes with a promoter peak to those without a promoter peak in the 15 24hr baseline sample. B-C) MA plot analyzing gene expression change after BFT2 treatment at 16 24 and 48 hours. Genes are colored according to the presence of a BFT2-opened peak or a 17 BFT2-closed peak in their promoter region. The dotted lines represent a log2 fold change in 18 expression of +/-O.5. The P-values were calculated by comparing the fold change in gene 19 expression for genes with a promoter BFT2-opened peak to those with a promoter BFT2-closed 20 peak. For all graphs, P-values were calculated using the Wilcoxon rank sum test. 21 22 Materials and Methods 1 2 Culture of HT-29/C1 cells: HT29/C1 cells were cultured at 37°C and 10% CO2. Cells were plated 3 at 20% confluency 4 days before addition of BFT2 toxin. At day 0, HT29/C1 cells were washed 4 five times with PBS, placed in minimal media (DMEM) without FBS or Pen/Strep and toxin was 5 added one time at a concentration of 100ng/ml. After toxin addition, cells were allowed to 6 grow at 37°C and 10% CO2 for 24 or 48 hours. 7 8 ATAC-seq transposition reaction: For all experiments, cell counts were obtained by trypsinizing 9 cells in 0.5% trypsin for 10 minutes at 37°C and then counting using a hemocytometer. Non-10 trypsinized cells were then scraped and 50,000 cells were added to an Eppendorf tube. ATAC-11 seq was performed using the protocol outlined by Buenrostro et al. (2015) . Briefly, cells were 12 washed with 50uL cold 1x PBS buffer, then centrifuged at 500g for 5 minutes at 4°C. Cells were 13 then resuspended in 50uL cold lysis buffer (10 mM Tris-HCl [pH 7.4], 10 mM NaCl, 3 mM MgCl 2 , 14 0.1% IGEPAL CA-630), gently lysed to preserve cell nuclei, and centrifuged again at 500g for 10 15 minutes at 4°C. Cells were then washed 3x with wash buffer (lysis buffer without igepal). After 16 each wash, cells were centrifuged at 500g for 5 minutes at 4°C. Cell nuclei were then 17 resuspended in the transposition reaction mix and incubated for 30 minutes at 37°C. DNA was 18 purified using a Qiagen MinElute PCR Purification Kit and eluted in 10uL elution buffer. DNA 19 was stored at -20°C until fragments were amplified via PCR. 20 PCR amplification following transposition: All of the DNA purified following transposition was 1 PCR amplified. To do so, the following were combined in a 0.2mL PCR tube: 10uL transposed 2 DNA, 10uL nuclease-free H2O, 2.5uL 25uM custom Nextera PCR primer 1, 2.5uL 25uM custom 3 Nextera barcoded PCR primer 2, 25uL NEBNext high-fidelity 2x PCR master mix. The 4 components were amplified as follows: 1 cycle of 72°C for 5 min, 98°C for 30 sec; 5 cycles of 5 98°C for 10 sec, 63°C for 30 sec, 72°C for 1 min. After initial amplification, the number of 6 additional cycles to run was determined using qPCR. For this, the following were combined in a 7 0.2mL PCR tube: 5uL of previously PCR-amplified DNA, 4.5uL of nuclease-free H2O, 0.25uL of 8 25uM custom Nextera PCR primer 1, 0.25uL of 25uM custom Nextera PCR primer 2, 5uL KAPA 9 SYBR FAST qPCR master mix (2x) (total reaction 15 ul). The components were amplified as 10 follows: 1 cycle of 98°C for 30 sec; 20 cycles of 98°C for 10 sec, 63°C for 30 sec, 72°C for 1 min. 11
To calculate the number of additional cycles of PCR needed, linear Rn versus cycle was plotted 12 and the cycle number that corresponds with 1/3 of the maximum fluorescent intensity was 13 determined. After the number of additional PCR cycles was determined, the remaining 45uL of 14 PCR product was run as follows: 1 cycle of 98°C for 30 sec; N cycles (as determined via qPCR) of 15 98°C for 10 sec 63°C for 30 sec, 72°C for 1 min. Finally, the amplified library was purified using 16 0.9x Ampure beads at room temperature, and eluted in 20uL RNAse-free H2O. 17 18 ATAC-seq data analysis: The 4nM pooled ATAC-seq library was sequenced on an Illumina HiSeq 19 using 50bp paired-end sequencing. For each sample, three biological replicates were 20 sequenced. After sequencing, the data was analyzed using the pipeline developed by the 21 Kundaje lab, as outlined on ENCODE (35). Briefly, reads were trimmed, aligned and filtered 22 using Bowtie2(36) and peaks were called using MACS2(37). The three replicate peak files were 1 combined in order to create one consensus file for each treatment condition using an 2 irreproducible discovery rate (IDR) threshold of 0.1. For all analyses, the "optimal set" 3 consensus file was used. Peak files for samples before and after BFT2 treatment were then 4 compared in order to create BFT2-opened peaks (peaks present after BFT2 treatment, but not 5 before) and BFT2-closed peak (peaks present before BFT2 treatment, but not after) files at 24 6 and 48 hours after treatment. The ChIPpeakAnno package was used to separate peaks into 7 specific regions of the genome (promoter, coding, intergenic) (38). The ChIPpeakAnno package 8 was also used to associate peaks located in promoter regions with their nearest downstream 9 genes. The haystack_bio package was used to identify transcription factor binding motifs (39). 10
For this analysis, C-G correction was turned off. For both the 24 hours and 48 hours analyses, 11 the BFT2-treated peak file was compared to the baseline peak file. A ratio greater than 1 12 represents transcription factor binding motifs that are present more frequently in the BFT2-13 treated peak file, while a ratio of less than 1 represents transcription factor binding motifs that 14 are present more frequently in the baseline peak file. The bedR package was used to calculate 15 the jaccard index for the overlap between identified peaks in our dataset and CTCF binding 16 peak data in Caco-2 cells, taken from the UCSC genome browser (40). 17 18 RNA-seq assay: Cells were washed once with PBS, collected using a cell scraper, and RNA was 19 extracted from cells using the Qiagen RNeasy mini kit. After RNA extraction, the RNA pellet was 20 flash frozen using 100% ethanol and dry ice. Samples were then stored at -80ºC. For library 21 preparation, samples were removed from storage, and mRNA was enriched using the NEBNext 22 Poly(A) mRNA Magnetic Isolation Module. Afterwards, a non-directional RNA-seq library was 1 constructed using the NEBnext Ultra RNA Library Prep kit from Illumina. The 2nM pooled RNA-2 seq library was sequenced using the Illumina HiSeq. For one sample, 50bp paired-end 3 sequencing was performed. For the other two samples, 50bp single-end sequencing was 4 performed. 5 6 RNA-seq data analysis: After sequencing, Kallisto was used to perform pseudoalignment of the 7 raw RNA-seq data (41). Then, Sleuth was used to quantify gene expression and perform 8 differential expression analyses (42). 9 10 Gene Set Enrichment Analysis: Gene set enrichment analysis was performed using all genes 11 with a P-value < 0.05 at 24 or 48 hours after BFT2 treatment. For this analysis, a ranklist was 12 first created by sorting the differentially expressed genes using the following formula: sign of 13 fold change × inverse P-value. This created a rank ordered list with the most significantly 14 upregulated genes at the top and the most significantly downregulated genes at the bottom. 15
The GSEA Pre-ranked tool was then run, using 1000 permutations, a classic (instead of 16 weighted) analysis, a minimum gene set size of 15 and a maximum gene set size of 1500. The 17 output of this analysis was then converted into graphical and tabular formats. 18 19 Statistics: To calculate the correlation between chromatin accessibility (ATAC-seq) and gene 20 expression (RNA-seq) at baseline and after BFT2 treatment, the Wilcoxon Rank Sum test was 21 used with an alpha of 0.05. To calculate the enrichment of transcription factor binding motifs in 22 (60.1%) 
